{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:42:06Z","timestamp":1793292126410,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:00:00Z","timestamp":1793404800000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0061"],"award-info":[{"award-number":["W81XWH-22-1-0061"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007419","name":"Lee Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007419","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R21EB036323"],"award-info":[{"award-number":["R21EB036323"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA259626"],"award-info":[{"award-number":["K08CA259626"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA249047"],"award-info":[{"award-number":["K08CA249047"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK097112"],"award-info":[{"award-number":["R01DK097112"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prro.2025.03.010","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T02:59:52Z","timestamp":1745290792000},"page":"e597-e605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Sedra","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella R.","family":"Pompa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Saylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi A.","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia C.","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3676-1800","authenticated-orcid":false,"given":"Thomas S.C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.03.010_bib0001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.03.010_bib0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0003","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.03.010_bib0004","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.010_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814347","article-title":"Emerging immunotherapy approaches for treating prostate cancer","volume":"24","author":"Meng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.prro.2025.03.010_bib0007","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrurol.2016.273","article-title":"Cardiovascular toxicities of systemic treatments of prostate cancer","volume":"14","author":"Veccia","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.prro.2025.03.010_bib0008","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41391-021-00348-x","article-title":"Hormone therapy use and the risk of acute kidney injury in patients with prostate cancer: A population-based cohort study","volume":"24","author":"Cardwell","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prro.2025.03.010_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.urology.2017.08.067","article-title":"Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer: A phase IV study","volume":"113","author":"Wallis","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.prro.2025.03.010_bib0010","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.prro.2025.03.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0012","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.03.010_bib0013","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.03.010_bib0014","first-page":"306","article-title":"Palliative radiotherapy for prostate cancer","volume":"28","author":"Boyer","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.prro.2025.03.010_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.prro.2025.03.010_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria For Adverse Events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.prro.2025.03.010_bib0017","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2152\/jmi.71.82","article-title":"Symptomatic adverse events of chemotherapy in breast cancer patients: using CTCAE, PRO-CTCAE, and EORTC QLQ-C30","volume":"71","author":"Arahori","year":"2024","journal-title":"J Med Invest"},{"key":"10.1016\/j.prro.2025.03.010_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2022.11.004","article-title":"Radiation therapy for painful bone metastases: Fractionation, recalcification, and symptom control","volume":"33","author":"Tseng","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2025.03.010_bib0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: Planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.prro.2025.03.010_bib0021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0022","article-title":"Radiation absorbed dose to spinal cord: Therapy of leptomeningeal metastasis using beta-emission radiopharmaceuticals","volume":"65","author":"Bao","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0023","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","article-title":"Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer","volume":"42","author":"Wei","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0024","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bulcan.2020.04.009","article-title":"[Mechanisms of radiation-induced lymphopenia and therapeutic impact]","volume":"107","author":"Cesaire","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.prro.2025.03.010_bib0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","article-title":"Lesion dosimetry for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer","volume":"64","author":"Grkovski","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.010_bib0026","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.03.010_bib0027","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12885-023-10725-5","article-title":"Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial)","volume":"23","author":"van der Sar","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.03.010_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: A randomized phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:58:11Z","timestamp":1782485891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1879850025000979"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.010","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}